Research confirms safety of COVID-19 vaccine in patients with IgG4-RD
Patients with immunoglobulin-G4-related disease (IgG4-RD) have high adherence to SARS-CoV-2 vaccination, with a generally favorable safety profile comparable to healthy controls, according to a study.
Researchers surveyed 20 patients with IgG4-RD and 40 healthy controls via telephone to gather data on vaccination status, adverse events (AEs), and COVID-19 infection outcomes.
Overall, 90% of patients with IgG4-RD received at least 1 vaccine dose, compared to 100% of healthy controls. Among vaccinated patients, 44.4% experienced systemic AEs, and 22.2% reported local AEs. In the healthy controls group, systemic and local AEs were reported in 50% and 67.5% of participants, respectively. No serious adverse reactions were observed in either group.
SARS-CoV-2 infection occurred in 60% of patients with IgG4-RD, with 41.67% on immunosuppressive therapy at the time. One patient developed severe COVID-19, but no disease flares followed vaccination or infection.
Reference
Mastromanno L, Giardina F, Gattamelata A, et al. Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease. Reumatismo. 2025;doi: 10.4081/reumatismo.2025.1744. Epub ahead of print. PMID: 39849976.